TheHER2CISH pharmDx™Kit in the assessment of breast cancer patients for anti-HER2 treatment
出版年份 2013 全文链接
标题
TheHER2CISH pharmDx™Kit in the assessment of breast cancer patients for anti-HER2 treatment
作者
关键词
-
出版物
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
Volume 13, Issue 3, Pages 233-242
出版商
Informa UK Limited
发表日期
2013-04-10
DOI
10.1586/erm.13.6
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab
- (2012) Nancy U. Lin et al. BREAST CANCER RESEARCH AND TREATMENT
- High Concordance Between Two Companion Diagnostics Tests
- (2011) Jan Trøst Jørgensen et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Immunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary approaches
- (2011) J Lehmann-Che et al. BRITISH JOURNAL OF CANCER
- Identifying responders to trastuzumab therapy in breast cancer
- (2011) Anja Brügmann et al. Future Oncology
- Loss of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Metastatic Sites of HER2-Overexpressing Primary Breast Tumors
- (2011) Naoki Niikura et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment of HER2-positive breast cancer: current status and future perspectives
- (2011) Carlos L. Arteaga et al. Nature Reviews Clinical Oncology
- Adjuvant Trastuzumab in HER2-Positive Breast Cancer
- (2011) Dennis Slamon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Testing HER2 in Breast Cancer
- (2011) Anja Brügmann et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- HER2 status in a population-derived breast cancer cohort: discordances during tumor progression
- (2010) Ulla Wilking et al. BREAST CANCER RESEARCH AND TREATMENT
- Determination ofHER2amplification in primary breast cancer using dual-colour chromogenicin situhybridization is comparable to fluorescencein situhybridization: a European multicentre study involving 168 specimens
- (2010) Tomás García-Caballero et al. HISTOPATHOLOGY
- Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer
- (2010) Harold J. Burstein et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy
- (2010) Howard A. Burris et al. JOURNAL OF CLINICAL ONCOLOGY
- Out of the darkness and into the light: bright field in situ hybridisation for delineation of ERBB2 (HER2) status in breast carcinoma
- (2010) A. M Gruver et al. JOURNAL OF CLINICAL PATHOLOGY
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Targeted HER2 Treatment in Advanced Gastric Cancer
- (2010) Jan Trøst Jørgensen ONCOLOGY
- Chromogenic In Situ Hybridization Is a Reliable Method for DetectingHER2Gene Status in Breast Cancer
- (2009) Yun Gong et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Loss of HER2 Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival Outcomes
- (2009) E. A. Mittendorf et al. CLINICAL CANCER RESEARCH
- Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology
- (2009) L. M. Ellis et al. CLINICAL CANCER RESEARCH
- Bright-field In Situ Hybridization for HER2 Gene Amplification in Breast Cancer Using Tissue Microarrays
- (2009) Glenn D. Francis et al. DIAGNOSTIC MOLECULAR PATHOLOGY
- The Correlation Between Dual-color Chromogenic In Situ Hybridization and Fluorescence In Situ Hybridization in Assessing HER2 Gene Amplification in Breast Cancer
- (2009) Marianne Pedersen et al. DIAGNOSTIC MOLECULAR PATHOLOGY
- The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine
- (2009) J. S. Ross et al. ONCOLOGIST
- Comparison of Chromogenic In Situ Hybridisation with Fluorescence In Situ Hybridisation and Immunohistochemistry for the Assessment of Her-2/neu Oncogene in Archival Material of Breast Carcinoma
- (2008) Alexios Pothos et al. ACTA HISTOCHEMICA ET CYTOCHEMICA
- Delineation of HER2 Gene Status in Breast Carcinoma by Silver in Situ Hybridization is Reproducible among Laboratories and Pathologists
- (2008) Antonino Carbone et al. JOURNAL OF MOLECULAR DIAGNOSTICS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started